Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Esco Lifesciences Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/esco-lifesciences-group" target="_blank" data-smartkarma-citation="entities:36570:1" rel="noopener">Esco Lifesciences Group (1891571D SP)</a>, a profitable lifesciences tool provider with a global presence, is looking to raise $300M in its upcoming HK IPO.  </li>
<li>The company clocked revenue of S$117M in 2019, which steadily rose to S$155M in 2020 and S$172M in 2021, representing CAGR of 21%, outpacing lifesciences equipment market growth of 10%.</li>
<li>In May 2021, Esco raised $200M through series-A fund raising with investors holding nearly 24% of the shares. This puts its valuation at around $840M.</li>
</ul>



Esco Lifesciences Group (1891571D SP), a profitable lifesciences tool provider with a global presence, is looking to raise $300M in its upcoming HK IPO.  
The company clocked revenue of S$117M in 2019, which steadily rose to S$155M in 2020 and S$172M in 2021, representing CAGR of 21%, outpacing lifesciences equipment market growth of 10%.
In May 2021, Esco raised $200M through series-A fund raising with investors holding nearly 24% of the shares. This puts its valuation at around $840M.


Esco Lifesciences (1891571D SP) Pre-IPO: A Profitable Revenue Growth Saga

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Agilent performed well in the fourth quarter and its revenues as well as earnings were vastly exceeding its forecasts as well as market expectations.</li><li>Revenue for the Agilent CrossLab Group in the fourth quarter was $381 million.</li><li>With each of their three business areas expanding by double digits for the year, Agilent have shown a broad-based strength.</li></ul>

Agilent performed well in the fourth quarter and its revenues as well as earnings were vastly exceeding its forecasts as well as market expectations.Revenue for the Agilent CrossLab Group in the fourth quarter was $381 million.With each of their three business areas expanding by double digits for the year, Agilent have shown a broad-based strength.

<ul><li>Agilent Technologies delivered an excellent quarterly result with earnings and revenue exceeding market expectations significantly.</li><li>The strong results were led by strength in its biggest markets i.e., chemical, energy, and pharma.</li><li>We provide the stock of Agilent Technologies with a ‘Hold’ rating with a revision in the target price.</li></ul>

Agilent Technologies delivered an excellent quarterly result with earnings and revenue exceeding market expectations significantly.The strong results were led by strength in its biggest markets i.e., chemical, energy, and pharma.We provide the stock of Agilent Technologies with a ‘Hold’ rating with a revision in the target price.

Agilent Technologies: New Launches In Mass Spectrometry & Other Drivers

Agilent Technologies / Equity Capital Markets

<ul><li>Agilent Technologies delivered a mixed result and failed to meet Wall Street expectations on the revenue front but delivered an earnings beat.</li><li>The lower-than-expected revenue growth was due to the lockdowns and the fact that the company closed its operations in Shanghai.</li><li>The momentum in the energy and chemical business continued to deliver 9% growth, overcoming the conflict in Ukraine and the shutdown of its primary GC facility.</li></ul>

Agilent Technologies delivered a mixed result and failed to meet Wall Street expectations on the revenue front but delivered an earnings beat.The lower-than-expected revenue growth was due to the lockdowns and the fact that the company closed its operations in Shanghai.The momentum in the energy and chemical business continued to deliver 9% growth, overcoming the conflict in Ukraine and the shutdown of its primary GC facility.

Agilent Technologies Inc.: Momentum From Cancer Diagnostics

Credit

<ul><li>Agilent ended the year 2021 on a highly positive note with a top-line of $6.32 billion and revenues growing by as much as $1 billion (around 15%).</li><li>The company provided analytical informatics and instruments to a wide customer range along with consumables and related services that ensure strong revenue stickiness.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Agilent ended the year 2021 on a highly positive note with a top-line of $6.32 billion and revenues growing by as much as $1 billion (around 15%).The company provided analytical informatics and instruments to a wide customer range along with consumables and related services that ensure strong revenue stickiness.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Agilent Technologies: Detailed Credit Analysis & Financial Strength Evaluation Report

United States

Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences, and chemical analysis industries. The Company offers electronic and bio-analytical measurement, semiconductor, and board testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Agilent Technologies (A US)

Esco Lifesciences (1891571D SP) Pre-IPO: A Profitable Revenue Growth Saga

Esco Lifesciences is looking to raise $300M through HK IPO. During 2019–2021, by leveraging on demand for its products, the company recorded...

Tina Banerjee

Agilent Technologies: Key Drivers

Agilent performed well in the fourth quarter and its revenues as well as earnings were vastly exceeding its forecasts as well as market...

Baptista Research

Agilent Technologies: New Launches In Mass Spectrometry & Other Drivers

Agilent Technologies delivered an excellent quarterly result with earnings and revenue exceeding market expectations significantly. The strong...

Baptista Research

Agilent Technologies Inc.: Momentum From Cancer Diagnostics

Agilent Technologies delivered a mixed result and failed to meet Wall Street expectations on the revenue front but delivered an earnings beat. The...

Baptista Research

Agilent Technologies: Detailed Credit Analysis & Financial Strength Evaluation Report

Agilent ended the year 2021 on a highly positive note with a top-line of $6.32 billion and revenues growing by as much as $1 billion (around...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)